ATE415476T1 - Partnern des ptb1 domäne aus fe65, herstellung und verwendungen davon - Google Patents

Partnern des ptb1 domäne aus fe65, herstellung und verwendungen davon

Info

Publication number
ATE415476T1
ATE415476T1 AT01907727T AT01907727T ATE415476T1 AT E415476 T1 ATE415476 T1 AT E415476T1 AT 01907727 T AT01907727 T AT 01907727T AT 01907727 T AT01907727 T AT 01907727T AT E415476 T1 ATE415476 T1 AT E415476T1
Authority
AT
Austria
Prior art keywords
partners
production
ptb1 domain
present
ptb1
Prior art date
Application number
AT01907727T
Other languages
English (en)
Inventor
Isabelle Maury
Luc Mercken
Alain Fournier
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0001628A external-priority patent/FR2804962B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE415476T1 publication Critical patent/ATE415476T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Respiratory Apparatuses And Protective Means (AREA)
  • Soft Magnetic Materials (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Thin Magnetic Films (AREA)
AT01907727T 2000-02-10 2001-02-07 Partnern des ptb1 domäne aus fe65, herstellung und verwendungen davon ATE415476T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0001628A FR2804962B1 (fr) 2000-02-10 2000-02-10 Partenaires du domaine ptb1 de fe65, preparation et utilisations
US19850000P 2000-04-18 2000-04-18

Publications (1)

Publication Number Publication Date
ATE415476T1 true ATE415476T1 (de) 2008-12-15

Family

ID=26212162

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01907727T ATE415476T1 (de) 2000-02-10 2001-02-07 Partnern des ptb1 domäne aus fe65, herstellung und verwendungen davon

Country Status (17)

Country Link
US (2) US6696273B2 (de)
EP (1) EP1257642B1 (de)
KR (1) KR100802687B1 (de)
AT (1) ATE415476T1 (de)
AU (2) AU2001235625B2 (de)
BR (1) BR0108247A (de)
CA (1) CA2399939A1 (de)
CY (1) CY1108758T1 (de)
DE (1) DE60136688D1 (de)
DK (1) DK1257642T3 (de)
ES (1) ES2315273T3 (de)
IL (1) IL151147A0 (de)
MX (1) MXPA02007620A (de)
NO (1) NO330798B1 (de)
NZ (1) NZ520697A (de)
PT (1) PT1257642E (de)
WO (1) WO2001059104A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10146737A1 (de) * 2001-09-22 2003-04-10 Aventis Pharma Gmbh Coniosulfide und deren Derivate, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69033772T2 (de) * 1989-11-02 2002-06-20 Dictytech Pty Ltd., Frenchs Forest Verbesserte plasmidvektoren für zelluläre schleimpilze der gattung dictyostelium
US5928882A (en) * 1997-10-24 1999-07-27 The Rockefeller University Treatment and prevention of neurodegenerative diseases using modulators of Fe65
AU1536399A (en) * 1997-11-26 1999-06-15 Genetics Institute Inc. Secreted proteins and polynucleotides encoding them
US6214582B1 (en) * 1998-11-16 2001-04-10 The Research Foundation Of State University Of Ny Y2H35 a strong IKK binding protein

Also Published As

Publication number Publication date
NO330798B1 (no) 2011-07-18
DE60136688D1 (de) 2009-01-08
WO2001059104A1 (fr) 2001-08-16
EP1257642B1 (de) 2008-11-26
NZ520697A (en) 2005-11-25
NO20023783L (no) 2002-09-09
US20020061553A1 (en) 2002-05-23
AU3562501A (en) 2001-08-20
IL151147A0 (en) 2003-04-10
KR20020079844A (ko) 2002-10-19
EP1257642A1 (de) 2002-11-20
US20040166109A1 (en) 2004-08-26
US6942982B2 (en) 2005-09-13
KR100802687B1 (ko) 2008-02-12
MXPA02007620A (es) 2002-12-13
PT1257642E (pt) 2009-01-30
NO20023783D0 (no) 2002-08-09
CY1108758T1 (el) 2014-04-09
US6696273B2 (en) 2004-02-24
CA2399939A1 (fr) 2001-08-16
ES2315273T3 (es) 2009-04-01
AU2001235625B2 (en) 2007-01-11
DK1257642T3 (da) 2009-03-30
BR0108247A (pt) 2002-11-05

Similar Documents

Publication Publication Date Title
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
TR200402704T4 (tr) Yeni fenil-propargileter türevleri
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
BR0317696A (pt) Composição para branqueamento
DE50310516D1 (de) Fredericamycin-derivate
DOP2001000297A (es) Nuevas imidazotriazinonas sustituidas
BRPI0414864A (pt) composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida
ATE291424T1 (de) Katechin und quercetin zur pharmazeutischen oder diätetischen verwendung
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
BR0209440A (pt) Sulfonamidas
ECSP024400A (es) Derivados de pleuromutilina que tiene actividad antibacteriana
MXPA02009313A (es) Acilsulfimidas heterociclicas, un metodo para su produccion, agentes que contienen las mismas y su uso como plaguicidas.
MA27169A1 (fr) Metabolites de l'acide (3-{ [(4-tertiobutylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetique
ATE313541T1 (de) Benzofuran derivate und ihre verwendung als antibakterielle wirkstoffe
WO2004039326A3 (en) Propofol with cysteine
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
BR0307696A (pt) Composição desodorante ou antitranspirante
ATE311429T1 (de) 8-tetradecenal als duft- oder aromastoff
EP1642969A4 (de) Fluoreszenzprotein und pigmentprotein
ATE415476T1 (de) Partnern des ptb1 domäne aus fe65, herstellung und verwendungen davon
CY1111004T1 (el) Χρησιμες συνθεσεις για τη ρυθμιση της δρασης του γονιδιου της παρκινης
DE602006002608D1 (de) 4-phenyl-5-oxo-l,4,5,6,7,8-hexahydrochinolin-derivate als arzneimittel zur behandlung von unfruchtbarkeit
WO2002032445A3 (de) Hemmung der interaktion zwischen oxidierte proteine und cd36 oder dessen wirkmechanismus
DE602005026565D1 (de) 5-(2,2-dimethyl-cyclopropyl)-3-methylpent-2-ennitril als geruchs- und geschmacksstoff
ATE232739T1 (de) Protein c zur behandlung von sichelzellanämie und thalassämie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1257642

Country of ref document: EP